Given the observed increase in CD8+ T-cell infiltration at the primary tumor site and decreased expression of checkpoint inhibitor markers on CD8+ T-cells following dual IPI-549/PD-L1 treatment, we characterized the impact of this novel treatment on CD8+ T-cell function. Here, CD8A is linked to neoplasm.